Safety, immunogenicity, and breakthrough infections during 1-year follow-up after COVISHIELD™ vaccination among healthcare workers in a teaching institute in North India: A prospective longitudinal study.

Vaxzevria (ChAdOx1-S recombinant) - University of Oxford, Emergent Biosolutions, Jenner Institute, Barinthus Bio, AstraZeneca

http://www.ncbi.nlm.nih.gov/pubmed/40115569

Arnab Ghosh; Ashish Bhalla; Indrakshi Sharma; Madhu Gupta; Mahesh Devnani; Mini P Singh; Ritin Mohindra; Sanjay Verma; Vikas Suri

Mar 21, 2025